Your browser doesn't support javascript.
loading
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
Zeng, Zhihong; Wang, Rui-Yu; Qiu, Yi Hua; Mak, Duncan H; Coombes, Kevin; Yoo, Suk Young; Zhang, Qi; Jessen, Katti; Liu, Yi; Rommel, Christian; Fruman, David A; Kantarjian, Hagop M; Kornblau, Steven M; Andreeff, Michael; Konopleva, Marina.
Affiliation
  • Zeng Z; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang RY; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Qiu YH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mak DH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Coombes K; Department of Biomedical Informatics, Ohio State University College of Medicine, Columbus, OH, USA.
  • Yoo SY; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang Q; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jessen K; Oncology-Rinat Research & Development, San Diego, CA, USA.
  • Liu Y; Wellspring Bioscience, San Diego, CA, USA.
  • Rommel C; Roche Innovation Center Basel, Basel, Switzerland.
  • Fruman DA; Institute for Immunology, and Department of Molecular Biology and Biochemistry, University of California-Irvine, Irvine, CA, USA.
  • Kantarjian HM; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kornblau SM; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Konopleva M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oncotarget ; 7(34): 55083-55097, 2016 Aug 23.
Article in En | MEDLINE | ID: mdl-27391151
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Neoplastic Stem Cells / Benzoxazoles / Leukemia, Myeloid / Apoptosis / TOR Serine-Threonine Kinases Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Oncotarget Year: 2016 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Neoplastic Stem Cells / Benzoxazoles / Leukemia, Myeloid / Apoptosis / TOR Serine-Threonine Kinases Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Oncotarget Year: 2016 Document type: Article